Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Rhythm Pharmaceuticals Inc
(NQ:
RYTM
)
47.03
+0.91 (+1.97%)
Streaming Delayed Price
Updated: 11:42 AM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rhythm Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
March 11, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
March 06, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Analyst Expectations For Rhythm Pharmaceuticals's Future
February 22, 2024
Via
Benzinga
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
February 22, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Preview: Rhythm Pharmaceuticals's Earnings
February 21, 2024
Via
Benzinga
Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
January 25, 2024
Via
Benzinga
The Analyst Verdict: Rhythm Pharmaceuticals In The Eyes Of 7 Experts
January 04, 2024
Via
Benzinga
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
February 22, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
February 08, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
February 07, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Analyst Expectations for Rhythm Pharmaceuticals's Future
December 07, 2023
Via
Benzinga
Earnings Scheduled For February 22, 2024
February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.
Via
Benzinga
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
January 31, 2024
Company to participate in fireside chats at Guggenheim’s 6th Annual Biotechnology Conference on Feb. 7 and TD Cowen 44th Annual Health Care Conference on March 5
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
2 biotechs with promising weight-loss drugs coming
January 16, 2024
Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co.
Via
MarketBeat
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
January 12, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
January 04, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates
January 04, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
December 15, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023
December 13, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rare Genetic Diseases Of Obesity-Focused Rhythm Pharma's Bardet-Biedl Syndrome Drug Meets Primary Goal In Pediatric Trial
December 06, 2023
During the R&D event for investors, Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) released new topline data from its Phase 3 pediatrics trial evaluating one year of setmelanotide in patients aged two and...
Via
Benzinga
Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event
December 06, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
November 13, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
November 07, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)
November 02, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
October 25, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders
October 19, 2023
EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
Earnings Scheduled For November 7, 2023
November 07, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
Via
Benzinga
Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023
October 17, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
October 13, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Morgan Stanley Maintains Equal-Weight Rating for Rhythm Pharmaceuticals: Here's What You Need To Know
October 10, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.